State Street’s Strongbridge Biopharma plc. SBBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-137,728
Closed -$281K 4876
2021
Q3
$281K Buy
137,728
+8,100
+6% +$18.9K ﹤0.01% 4228
2021
Q2
$385K Sell
129,628
-614,515
-83% -$1.62M ﹤0.01% 3958
2021
Q1
$2.05M Buy
744,143
+55,741
+8% +$168K ﹤0.01% 3427
2020
Q4
$1.67M Sell
688,402
-34,850
-5% -$84K ﹤0.01% 3427
2020
Q3
$1.52M Sell
723,252
-14,051
-2% -$47.4K ﹤0.01% 3304
2020
Q2
$2.79M Sell
737,303
-19,637
-3% -$58.8K ﹤0.01% 3048
2020
Q1
$1.43M Buy
756,940
+80,569
+12% +$209K ﹤0.01% 3198
2019
Q4
$1.41M Buy
676,371
+41,284
+7% +$79.2K ﹤0.01% 3347
2019
Q3
$1.52M Buy
635,087
+63,759
+11% +$171K ﹤0.01% 3303
2019
Q2
$1.79M Buy
571,328
+484,843
+561% +$1.78M ﹤0.01% 3282
2019
Q1
$431K Sell
86,485
-2,678
-3% -$13.2K ﹤0.01% 3464
2018
Q4
$399K Buy
89,163
+4,454
+5% +$21.7K ﹤0.01% 3479
2018
Q3
$411K Buy
84,709
+66,495
+365% +$340K ﹤0.01% 3502
2018
Q2
$109K Sell
18,214
-356,429
-95% -$2.61M ﹤0.01% 3623
2018
Q1
$3.32M Buy
374,643
+180,874
+93% +$1.35M ﹤0.01% 2968
2017
Q4
$1.4M Buy
193,769
+84,666
+78% +$529K ﹤0.01% 3282
2017
Q3
$754K Buy
109,103
+46,997
+76% +$324K ﹤0.01% 3428
2017
Q2
$443K Buy
+62,106
New +$287K ﹤0.01% 3433

State Street's SBBP Position: Q4 2021 in Review

State Street sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 137,728 shares — an estimated $281K sold.

State Street first reported a position in SBBP in Q2 2017 and held it in 18 quarters. The position peaked at $3.32M in Q1 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.

  • State Street reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
  • State Street sold 137,728 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $281K.
  • State Street first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 18 quarters.
  • State Street's Strongbridge Biopharma plc. position peaked at $3.32M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.

Based on State Street's 13F filing for Q4 2021, filed 14 Feb 2022.